A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Inclusion Criteria:
Exclusion Criteria:
Columbus, Ohio 43210, United States
Rio de Janeiro, 22775 001, Brazil
Chaoyang District, 100020, China
Tianjin, 300320, China
Ostrava - Poruba, 708 52, Czechia
Prague, 128 08, Czechia
Athens Attica, 115 28, Greece
Thessalonikis, 570 10, Greece
Gunma, 371-0034, Japan
Kamakura-shi, 247-8533, Japan
Nishinomiya Shi, 663 8501, Japan
Shiwa-gun, 028-3695, Japan
Brzozów, 36-200, Poland
Olsztyn, 10-228, Poland
Szczecin, 71-252, Poland
Warsaw, 02-781, Poland
Jeollanam-do, 58128, South Korea
Ankara, 06200, Turkey (Türkiye)